Published: August 17, 2026 at 9:02 am
Redx Pharma, a drug discovery and development company, has sealed a long-term funding deal that will see it list on the US-based Nasdaq exchange as Fibrx Therapeutics.
Based in Macclesfield, Redx is a clinical-stage biotechnology company focused on the development of novel, small molecule, targeted medicines for the treatment of fibrotic disease.
The news follows the announcement that Redx and Sky Bioscience Inc have agreed a ‘transaction agreement’ amid a $125 million financing deal with new and existing investors.